These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 1905991)

  • 21. Addition of desmopressin to recombinant human erythropoietin in treatment of haemostatic defect of uraemia.
    Jacquot C; Masselot JP; Berthelot JM; Peterlongo F; Castaigne JP
    Lancet; 1988 Feb; 1(8582):420. PubMed ID: 2893223
    [No Abstract]   [Full Text] [Related]  

  • 22. Desmopressin acetate in postoperative bleeding.
    Smith RC
    DICP; 1990 May; 24(5):475-6. PubMed ID: 2188433
    [No Abstract]   [Full Text] [Related]  

  • 23. Treatment of the bleeding tendency in uremia with cryoprecipitate.
    Maierhoter W; Adams MB; Kleinman JG; Roth DA
    N Engl J Med; 1981 Sep; 305(11):645. PubMed ID: 6790987
    [No Abstract]   [Full Text] [Related]  

  • 24. Cryoprecipitate shortens the bleeding time and reduces bleeding complications in patients with uremia.
    Jubelirer SJ; Janson PA; Weinstein MJ; Deykin D
    Trans Assoc Am Physicians; 1980; 93():182-91. PubMed ID: 6787774
    [No Abstract]   [Full Text] [Related]  

  • 25. Comparing efficacy and safety of fibrinogen concentrate to cryoprecipitate in bleeding patients: a systematic review.
    Jensen NH; Stensballe J; Afshari A
    Acta Anaesthesiol Scand; 2016 Sep; 60(8):1033-42. PubMed ID: 27109179
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [A case of von Willebrand's disease--successful application of 1-deamino-8-D-arginine vasopressin (DDAVP) to ovarian bleeding].
    Shiraishi K; Ebata H; Sato K; Tanaka M; Nouno R; Mashiko N; Yamaguchi G; Kubo Y; Tanikawa K; Ide K
    Rinsho Ketsueki; 1983 Dec; 24(12):1674-9. PubMed ID: 6608600
    [No Abstract]   [Full Text] [Related]  

  • 27. Recombinant factor VIIa in severe uremic bleeding.
    Révész T; Arets B; Bierings M; van den Bos C; Duval E
    Thromb Haemost; 1998 Aug; 80(2):353. PubMed ID: 9716175
    [No Abstract]   [Full Text] [Related]  

  • 28. Incidence of infectious and noninfectious side effects in hemophilia patients in the new German Federal States during treatment with cryoprecipitate.
    Lenk H; Schneider M
    Semin Thromb Hemost; 2002 Apr; 28 Suppl 1():51-6. PubMed ID: 12016579
    [No Abstract]   [Full Text] [Related]  

  • 29. Control of bleeding in severely uremic patients undergoing oral surgery.
    Buckley DJ; Barrett AP; Koutts J; Stewart JH
    Oral Surg Oral Med Oral Pathol; 1986 Jun; 61(6):546-9. PubMed ID: 2941716
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The cryoprecipitate: that old unknown.
    Blasi A; Beltran J; Pereira A; Puig L
    Rev Esp Anestesiol Reanim; 2015 Apr; 62(4):204-12. PubMed ID: 25561426
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Desmopressing (DDAVP) treatment in patients with bleeding tendency].
    Bairey O; Inbal A
    Harefuah; 1993 Aug; 125(3-4):105-7. PubMed ID: 8225075
    [No Abstract]   [Full Text] [Related]  

  • 32. Tranexamic acid and uremic bleeding: evidence-based treatment recommendations.
    Downey P; Tagle R; Pereira J; Mezzano D
    Nat Clin Pract Nephrol; 2007 Jun; 3(6):E2; author reply E3. PubMed ID: 17525710
    [No Abstract]   [Full Text] [Related]  

  • 33. Estrogen therapy of uremic bleeding.
    McCarthy ML; Stoukides CA
    Ann Pharmacother; 1994 Jan; 28(1):60-2. PubMed ID: 8123965
    [No Abstract]   [Full Text] [Related]  

  • 34. Inhibitor to factor VIII in a non-haemophilic patient: evaluation of the response to DDAVP and the in vitro kinetics of factor VIII. A case report.
    Chistolini A; Ghirardini A; Tirindelli MC; Moretti T; Mancini F; Di Paolantonio T; Mariani G
    Nouv Rev Fr Hematol (1978); 1987; 29(4):221-4. PubMed ID: 3122176
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Unconventional methods of the treatment of blood coagulation disorders in hemophilia patients].
    Kowalewski J
    Acta Haematol Pol; 1987; 18(1-2):127-30. PubMed ID: 3124484
    [No Abstract]   [Full Text] [Related]  

  • 36. A hemorrhagic syndrome of the elderly patient caused by anti-factor VIII antibodies.
    Vivaldi P; Savino M; Mazzon C; Rubertelli M
    Haematologica; 1993; 78(4):245-8. PubMed ID: 8294058
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of DDAVP and cryoprecipitate in mild to moderate haemophilia A and von Willebrand's disease.
    Berry EW
    Prog Clin Biol Res; 1990; 324():269-78. PubMed ID: 2106689
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The efficacy and safety of cryoprecipitate in the treatment of acquired hypofibrinogenaemia.
    Idris SF; Hadjinicolaou AV; Sweeney M; Winthrop C; Balendran G; Besser M
    Br J Haematol; 2014 Aug; 166(3):458-61. PubMed ID: 24725203
    [No Abstract]   [Full Text] [Related]  

  • 39. Plasma exchange donation of cryoprecipitate after DDAVP stimulation: an alternative source of factor VIII.
    McLeod BC; Scott JP
    Prog Clin Biol Res; 1990; 324():189-98. PubMed ID: 2106687
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.